Sign In

Mike Hoerres

Commercialization and Growth Advisor - Life Sciences

Mike Hoerres is a seasoned life sciences executive with extensive experience in biotechnology and healthcare. He is currently a Board Member at AEGEA BIOTECHNOLOGIES, having joined the company in June 2024.3 Hoerres has a strong background in strategic advising and consulting for life science tools, diagnostics, and medical devices.1

Career Highlights

  • Founder of Aquinas Life Science Advisors, LLC (January 2023 - Present)1
  • Interim President at Cernostics, a Castle Biosciences Company (January 2022 - December 2022)1
  • Chief Executive Officer at Cernostics, Inc. (June 2015 - December 2021)1
  • Principal, Office of Strategic Industry Partnerships at Geisinger Health System (February 2010 - May 2015)12

Expertise

Hoerres has significant experience in:

  • Commercialization of diagnostic technologies
  • Business development in the life sciences sector
  • Strategic partnerships and collaborations
  • Integration of acquired companies

His work at Cernostics led to the development of TissueCypher, an innovative diagnostic test for predicting esophageal cancer in patients with Barrett's Esophagus.1

Mike Hoerres holds a bachelor's degree in biochemistry from the University of Wisconsin–Milwaukee and a master's degree in molecular immunology from San Diego State University.2

Highlights

Jun 18 · linkedin

DNA amplification is a cornerstone of molecular biology, enabling multibillion-dollar industries including diagnostics and life science research. Switch-Blocker designs and assays developed by Lyle Arnold, Ph.D. and colleagues at Aegea Biotechnologies stand out as the most sensitive and specific for DNA mutation detection when used in conjunction with amplification technologies like PCR and NGS. Liquid biopsy companies often utilize machine learning tactics to enhance sensitivity claims, yet for single-copy detection from a blood sample, Switch-Blockers are unmatched. This patented approach boosts highly discriminating blockers (Switch) concentrations at mutation/variant sites, enabling single-copy detection in vast excesses of normal/wild-type DNA.  Congratulations to Lyle and the Aegea Biotechnologies team for their exceptional contributions! #DNAMutation #LifeScienceTools #MRD #EarlyDetection

Jun 14 · linkedin

Great to witness a successful IPO in the tools and dx space! Recently visited the Tempus facilities at ASCO and was amazed by the impressive lineup of Illumina sequencers in their ultra-modern clinical lab. The ongoing IP battle with Guardant adds an interesting dynamic to the industry. Congratulations to Ezra Cohen, CMO, and the entire team on these remarkable achievements! #IPO #ToolsandDX #Tempus #ASCO #Illumina #Guardant #ClinicalLab #Innovation

Related Questions

What are Mike Hoerres' main responsibilities at AEGEA Biotechnologies?
How did Mike Hoerres contribute to the success of Cernostics?
What is the significance of TissueCypher in the field of diagnostics?
How did Mike Hoerres' experience at Geisinger Ventures shape his career?
What are Mike Hoerres' educational background and qualifications?
Mike Hoerres
Mike Hoerres, photo 1
Mike Hoerres, photo 2
Add to my network

Location

San Diego, California, United States